Novo Nordisk A/S (NYSE:NVO) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received an average recommendation of “Hold” from the nineteen analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $64.9375.

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday, August 27th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. BMO Capital Markets restated a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th.

Novo Nordisk A/S Stock Down 0.0%

Novo Nordisk A/S stock opened at $46.59 on Monday. The company has a market cap of $208.02 billion, a PE ratio of 11.39, a price-to-earnings-growth ratio of 1.56 and a beta of 0.74. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The stock’s 50 day moving average price is $47.93 and its 200 day moving average price is $43.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a $0.5786 dividend. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 20.05%.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $287,660,000. Boston Partners acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $310,199,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Voloridge Investment Management LLC grew its position in shares of Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after purchasing an additional 4,302,126 shares during the period. Finally, Maverick Capital Ltd. purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at $76,444,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.